Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning and the news behind them! 
Via InvestorPlace
News headline image
Why bluebird bio Is Trading Higher By Around 19%; Here Are 31 Stocks Moving Premarket ↗
Gainers FOXO Technologies Inc. (NYSE: FOXO) rose 161% to $10.50 in pre-market trading after dipping 52% on Friday. 
Via Benzinga
News headline image
US Stock Futures Down Ahead Of Fed's Rate Decision This Week, Crude Oil Drops Over 1% ↗
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording losses on Friday. All the three major indices recorded losses last week, with the Dow Jones dropping... 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About bluebird bio ↗
  Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings: 
Via Benzinga
News headline image
Bluebird's Gene Therapy Scores US Approval For Genetic Blood Disorder, Probably The Most Expensive ↗
 
Via Benzinga
News headline image
AutoZone, bluebird bio And 3 Stocks To Watch Heading Into Monday ↗
With US stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
FDA Okays bluebird bio's $3M Gene Therapy For Rare Neurological Disorder In Boys: What Investors Should Know ↗
Biotechnology company, bluebird bio, Inc. (NASDAQ: BLUE) announced late Friday that the Food and Drug Administration approved its gene therapy for a rare neurodegenerative disease. 
Via Benzinga
News headline image
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)
From bluebird bio, Inc.
Via Business Wire
News headline image
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
News headline image
Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall
From bluebird bio, Inc.
Via Business Wire
News headline image
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
News headline image
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
News headline image
bluebird bio Announces September Investor Events
From bluebird bio, Inc.
Via Business Wire
News headline image
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday ↗
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday. 
Via Benzinga
News headline image
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66. 
Via Benzinga
News headline image
Dear AAPL Stock Fans, Mark Your Calendars for Sept. 7 ↗
Fans of Apple (AAPL) stock will want to keep their calendars open for Sept. 7 as that's reportedly when its next event will take place. 
Via InvestorPlace
News headline image
BLUE Stock Moves as FDA Approves Bluebird Bio’s Gene Therapy ↗
Bluebird Bio (BLUE) stock is on the move Thursday following FDA approval for beta-thalassemia treatment ZYNTEGLO in adults and children. 
Via InvestorPlace
News headline image
Bed Bath & Beyond, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday ↗
  Bed Bath & Beyond Inc. (NASDAQ: BBBY) fell 23.3% to $17.71 following a Form 144 filing by RC Ventures, which suggested the firm proposed to sell 7.78 million common shares and certain call options.... 
Via Benzinga
News headline image
Benzinga Before The Bell: Tesla Model Y Delivery Wait Time Shortened In China, Mark Zuckerberg's Sister Emphasizes On Evolution Of Web3, Amazon Succumbs To TikTok Fever And Other Top Financial Stories Thursday, August 18 ↗
CNBC 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time to take a look at the biggest pre-market stock movers for Thursday and the news that's got those shares moving! 
Via InvestorPlace
News headline image
This Healthcare Stock Is Trading Lower By 29%: Here Are 29 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Cisco, Keysight Technologies And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗
Wolfspeed, Inc. (NYSE: WOLF) rose 20.7% to $103.40 in pre-market trading after the company reported better-than-expected Q4 results. 
Via Benzinga
News headline image
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Bluebird Secures FDA Nod For Genetic Blood Disease Candidate ↗
The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ: BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult... 
Via Benzinga
News headline image
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
News headline image
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
News headline image
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday ↗
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. 
Via Benzinga
News headline image
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US ↗
 
Via Benzinga
News headline image
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD.... 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.